showed the marked growth suppression of MPC-1 À immature myeloma cells, but not MPC-1 þ mature myeloma cells in the MM2 case. In the primary myeloma cells from 20 cases, we summarized that the combination of Dex with baicalein showed consistent growth suppression in MPC-1 À immature myeloma cells from all cases, and MPC-1 þ mature myeloma cells were significantly suppressed in seven out of 20 cases.
Chronic idiopathic myelofibrosis expressing a novel type of TEL-PDGFRB chimaera responded to imatinib mesylate therapy Leukemia (2007) Constitutive activation of platelet-derived growth factor receptor (PDGFR) is one of the features of myeloproliferative disease (MPD). 1 PDGFR is a member of type III receptor tyrosine kinase that transmits mitotic signals in cells of mesenchymal origin. Both PDGFRA and PDGFRB genes, located on chromosomes 4q12 and 5q33 respectively, form fusion gene as a result of chromosome translocation. Representative examples are TEL-PDGFRB in t(5;12)(q33;p13) 2 and FIP1L1-PDGFRA in del(4)(q12), 3 both of the gene products known to have ligandindependent kinase activity. The former is observed in chronic myelomonocytic leukaemia (CMMoL) as well as other MPDs with eosinophilia, whereas the latter has been reported in hypereosinophilic syndrome (HES).
We report here a case of chronic idiopathic myelofibrosis (CIMF) with t(5;12)(q33;p13), which transformed to acute myelogenous leukaemia (AML). This case is unique in two aspects: (1) this is the first report of CIMF with TEL-PDGFRB fusion and (2) a novel type of TEL-PDGFRB fusion transcript that retained the internal and ETS domains of TEL was expressed. The leukaemic cells responded well to a series of chemotherapy, which was followed by administration of imatinib mesylate, a kinase inhibitor for both PDGFR and ABL. It gave a partial cytogenetic response but failed to maintain a remission of leukaemia. This case implies the existence of various types of TEL-PDGFRB fusion gene with possible impact on the phenotype of the disease.
A 37-year-old male presented with nasal and gingival bleeding in August 2005. He showed marked hepatosplenomegaly at presentation: spleen was palpable 10 cm below the left costal margin, and liver 2 cm below the right costal margin. Laboratory examination revealed a haemoglobin level of 7.6 g/ dl, a white blood cell count of 2.8 Â 10 9 /l (13.5% blasts) and a platelet count of 9.0 Â 10 9 /l. Six per cent erythroblasts as well as dacryocytes were observed in the peripheral blood. The bone marrow could hardly be aspirated. Histological examination of the biopsied specimen showed marked myelofibrosis accompanied by focal proliferation of blast-like cells and megakaryocytes among reticulin fibres. The blastic cells in the peripheral blood were negative for myeloperoxidase, nonspecific esterase, CD13 and CD41, but positive for CD33 (94.2%), CD34 (78.8%), CD56 (92.1%) and HLA-DR (88.4%). Because neither lymphoid markers nor electron microscopic platelet peroxidase activities were detected in the leukaemic cells, he was diagnosed as AML M0 according to the FAB classification. The preceding history of slight leukocytosis (15.6 Â 10 9 /l) at 16 months before the diagnosis and the presence of severe myelofibrosis with massive splenomegaly and tear drop cells at presentation suggested that his leukaemia had been transformed from CIMF. Cytogenetic analysis of the peripheral blood cells showed abnormality of 46, XY, t(5;12)(q33;p13) [ 
. The patient was treated with induction course of chemotherapy consisting of cytarabine and idarubicin. After one course of chemotherapy, complete remission was achieved morphologically with improvement of myelofibrosis and recovery of platelet count. Additional two courses of chemotherapy with high-dose cytarabine for consolidation maintained morphological remission. Although cells with normal karyotype transiently appeared in the bone marrow during these courses of chemotherapy, the stem line clone carrying t(5;12) never disappeared and formed 100% of the dividing cells at the end of the consolidation therapy. Imatinib mesylate treatment (400 mg/day) was commenced in November 2005 and continued for 3 months until February 2006 when anaemia and leukocytopenia emerged accompanied by high fever and unconsciousness. Serum calcium and C-reactive protein levels increased up to 13.8 and 14.43 mg/dl, respectively. Bone scintigraphy showed abnormal uptakes in multiple regions such as right shoulder and left femur, suggesting the relapse of AML with multiple blastoma in the bone. Although the bone marrow aspirate became dry again, chromosome analysis revealed reemergence of normal clone but also the sidelines with the same additional abnormalities as those seen at presentation. Despite the intensive chemotherapy with cytarabine and idarubicin, leukaemic cells reappeared in the peripheral blood. The patient succumbed to multiple organ failure owing to disseminated intravascular coagulation syndrome and died in March 2006 (Figure 1) .
Based on the physical and laboratory findings, and the clinical course, this patient was diagnosed as AML transformed from CIMF. No t(5;12)(q33;p13) has been reported in CIMF cases so far. Nested reverse transcription-PCR experiment of the peripheral blood specimen at diagnosis using HemaVision leukaemia typing/subtyping system (DNA Technology A/S, Aarhus, Denmark) showed single TEL-PDGFRB fusion product that was larger in size than expected. Sequencing analysis of the product revealed in-frame fusion between exon 7 of TEL gene and exon 10 of PDGFRB gene (TEL7-PDGFRB10; Figure 2 ). All other common leukaemogenic fusion genes screened by HemaVision including major BCR-ABL were not detected. JAK2 V617F , frequently found in MPDs including CIMF, was not detected in this case.
In all previously reported cases with the t(5;12)(q33;p13) translocation, exon 4 of TEL gene was fused in-frame to exon 11 of PDGFRB gene (2) (TEL4-PDGFRB11). TEL4-PDGFRb11 consists of the sterile-alpha-motif (SAM) domain of TEL, which fuses to the transmembrane and catalytic domains of PDGFRb. The SAM domain of TEL is known to act as the interface for Letters to the Editor homo-oligomerization and thus make oncogenic conversion of the catalytic domain provided from PDGFRb. 4 In the fusion protein encoded by TEL7-PDGFRB10, the internal and ETS domains of TEL are also included in the chimaeric protein, which differs from previously reported TEL4-PDGFRb11. Corepressor N-CoR and histone deacetylase-3 are known to bind to TEL via this internal domain and have important roles in transcription-repressive activity of TEL and its chimaeric proteins. On the other hand, it is interesting to note that no other TEL-related chimaeric molecules fused to tyrosine kinase possess the ETS DNA-binding domain. These additional internal and ETS domains in TEL7-PDGFRb10 may modify the original function of TEL4-PDGFRb11.
There is an example presenting that the internal domain of TEL in TEL-tyrosine kinase chimaera may have an impact on the disease phenotype. TEL-TRKC fusion gene is formed as a result of t(12;15)(p13;q25) and encodes activated kinase. It is unique in that it is found in both solid tumours and leukaemia, 5 with a single exon difference, and codes for the internal domain of TEL between the two sets of cancer phenotypes. Mouse models have suggested that the presence of the internal domain of TEL may alter the phenotype of the tumours. 6 Given the fact that this novel TEL7-PDGFRb10 fusion was observed in a CIMF case, unknown function of the internal and ETS domains of TEL in the context of chimaera may be responsible for the disease phenotype.
It is important to stress that the t(5;12)(q33;p13)-carrying clone without additional chromosomal abnormalities remained throughout the clinical course, even when morphological complete remission of AML was obtained. This indicates that t(5;12)(q33;p13) may have been the first hit in stem cell to cause CIMF, which later transformed into AML with additional genetic hit(s).
Imatinib is a biochemical inhibitor for PDGFR 7 as well as ABL and c-kit. It has recently been reported that imatinib is clinically effective for MPD with aberrant activation of PDGFR kinase such as HES with FIP1L1-PDGFRA 3 and CMMoL or other MPDs with TEL-PDGFRB. 8 Although the treatment period may not have been enough in this case, some cytogenetic response after three-month administration of imatinib was observed. This case suggests that tyrosine kinase activation other than JAK2 V617F mutation may also be responsible for the pathogenesis of CIMF and such cases may respond to imatinib therapy. School of Medicine, Shimotsuga-gun, Tochigi, Japan E-mail: kinukom-tky@umin.ac.jp
